OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 18:57 UTC. Every row links to its source record.

FLI1 Fli-1 proto-oncogene, ETS transcription factor

ENSG00000151702 · protein coding · Open Targets profile

Sequence-specific transcriptional activator (PubMed:24100448, PubMed:26316623, PubMed:28255014). Recognizes the DNA sequence 5'- C[CA]GGAAGT-3'. {ECO:0000269|PubMed:24100448, ECO:0000269|PubMed:26316623, ECO:0000269|PubMed:28255014}.

In 14 of 15 cancers, the evidence for FLI1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751Ewing sarcomaEwing sarcomaosteosarcomaosteosarcomaosteosarcoma: somatic 0.61Ewing sarcoma/peripheral primitive neur…Ewing sarcoma/peripheral primitive neuroectodermal tumorEwing sarcoma/peripheral primitive neuroectodermal tumor: somatic 0.61rhabdomyosarcomarhabdomyosarcomarhabdomyosarcoma: somatic 0.61malignant peripheral nerve sheath tumormalignant peripheral nerve sheath tumormalignant peripheral nerve sheath tumor: somatic 0.61desmoplastic small round cell tumordesmoplastic small round cell tumordesmoplastic small round cell tumor: somatic 0.61alveolar rhabdomyosarcomaalveolar rhabdomyosarcomaalveolar rhabdomyosarcoma: somatic 0.61synovial sarcomasynovial sarcomasynovial sarcoma: somatic 0.61leiomyosarcomaleiomyosarcomaleiomyosarcoma: somatic 0.61olfactory neuroblastomaolfactory neuroblastomaolfactory neuroblastoma: somatic 0.61hematopoietic and lymphoid cell neoplasmhematopoietic and lymphoid cell neoplasmhematopoietic and lymphoid cell neoplasm: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61Askin tumorAskin tumorAskin tumor: somatic 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61undifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Ligand
PROTAC
Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.24476000666618347 (upper bound 0.3891400098800659). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of FLI1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of FLI1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.